Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Thomason

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Bioorganic & Medicinal Chemistry Letters|September 16, 2006
Inhibition of Tpl2 kinase and TNFalpha production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritisYonghan Hu, Neal Green, Lori K Gavrin, et al.
Bioorganic & Medicinal Chemistry|October 12, 2005
Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritisYonghan Hu, Jason S Xiang, Martin J DiGrandi, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2018
Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11Matthew W Martin, Jennifer Y Lee, David R Lancia, et al.
Bioorganic & Medicinal Chemistry Letters|September 17, 2005
Inhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationshipsLori Krim Gavrin, Neal Green, Yonghan Hu, et al.
Annals of Hepatology|December 15, 2011
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patientsDavid R Nelson, Stefan Zeuzem, Pietro Andreone, et al.
Injury|August 26, 2022
Assessment of safety and effectiveness of non-neurosurgical management for minimal traumatic brain injury (TBI)Jeffrey W Chen, Aaron Yengo-Kahn, Silky Chotai, et al.
Journal of Medicinal Chemistry|May 13, 2017
Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug DesignKatherine L Lee, Catherine M Ambler, David R Anderson, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Bioorganic & Medicinal Chemistry Letters|September 16, 2006
Inhibition of Tpl2 kinase and TNFalpha production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritisYonghan Hu, Neal Green, Lori K Gavrin, et al.
Bioorganic & Medicinal Chemistry|October 12, 2005
Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritisYonghan Hu, Jason S Xiang, Martin J DiGrandi, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2018
Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11Matthew W Martin, Jennifer Y Lee, David R Lancia, et al.
Bioorganic & Medicinal Chemistry Letters|September 17, 2005
Inhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationshipsLori Krim Gavrin, Neal Green, Yonghan Hu, et al.
Annals of Hepatology|December 15, 2011
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patientsDavid R Nelson, Stefan Zeuzem, Pietro Andreone, et al.
Injury|August 26, 2022
Assessment of safety and effectiveness of non-neurosurgical management for minimal traumatic brain injury (TBI)Jeffrey W Chen, Aaron Yengo-Kahn, Silky Chotai, et al.
Journal of Medicinal Chemistry|May 13, 2017
Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug DesignKatherine L Lee, Catherine M Ambler, David R Anderson, et al.
Pageof 5